Pro Life Medica Sp. z o.o.

Research site

Poland Ul. Wladyslawa Kunickiego 26a, 20-412 Lublin, Poland

1 trial recruiting
Rheumatoid arthritis · Psoriasis · Psoriatic arthropathy
Adult patients

About Specializations

Pro Life Medica Sp. z o.o. in Lublin, Poland specialises in clinical trials of conditions such as Rheumatoid arthritis, Psoriasis, Psoriatic arthropathy, Parkinson's disease, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Wladyslawa Kunickiego 26a20-412 LublinPoland

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 15

More sites in Lublin Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

18 clinical trials

Parkinson's disease

Recruiting

Study on the Safety and Effectiveness of NEU-411 for Patients with Early Parkinson's Disease

Investigational

Study on the Safety and Effectiveness of NEU-411 for Patients with Early Parkinson's Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Neuron23 Inc.

Contact Research Centre

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Etanercept
Sponsor:Mabxience Research S.L.

Contact Research Centre

Psoriasis

Not recruiting

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Apremilast
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Sonelokimab
Sponsor:MoonLake Immunotherapeutics AG

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Barzolvolimab
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Rheumatoid arthritis

Not recruiting

Study on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo

Study on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Abatacept
Sponsor:Dr Reddy's Laboratories Limited

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Guselkumab
Sponsor:Janssen Cilag International

Contact Research Centre

Back pain

Not recruiting

Study on the Effects of VER-01, Ibuprofen, and Paracetamol for Patients with Chronic Non-Specific Low Back Pain

Registered drug

Study on the Effects of VER-01, Ibuprofen, and Paracetamol for Patients with Chronic Non-Specific Low Back Pain

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Dronabinol
Sponsor:Vertanical GmbH

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:ISIS 678354 sodium salt
Sponsor:Ionis Pharmaceuticals Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Salbutamol
Sponsor:AstraZeneca AB

Contact Research Centre

Endocrine ophthalmopathy

Not recruiting

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:VRDN-003
Sponsor:Viridian Therapeutics Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites